TABLE 4.
Change in weight, anthropometric measures, body composition, and metabolic markers in women randomly assigned to vitamin D treatment who did or did not become 25(OH)D replete (≥32 ngm/L) by 12 mo1
| 25(OH)D <32 ng/mL |
25(OH)D ≥32 ng/mL |
|||||||||||
| n | Baseline | n | 12 mo | Percentage | n | Baseline | n | 12 mo | Percentage | 2 | 3 | |
| Serum 25(OH)D (ng/mL) | 40 | 19.2 ± 5.54 | 40 | 26.4 ± 4.6 | 37.2 | 53 | 23.5 ± 5.7 | 53 | 41.5 ± 6.5 | 76.8 | <0.001 | <0.001 |
| Weight (kg) | 40 | 89.7 ± 16.6 | 40 | 84.1 ± 16.7 | −6.2 | 53 | 85.7 ± 14.2 | 53 | 77.2 ± 14.3 | −9.9 | 0.05 | 0.07 |
| BMI (kg/m2) | 40 | 33.1 ± 5.8 | 40 | 31.0 ± 5.7 | −6.3 | 53 | 31.5 ± 5.1 | 53 | 28.4 ± 5.3 | −9.9 | 0.06 | 0.02 |
| Waist circumference (cm) | 40 | 100.9 ± 12.2 | 40 | 98.4 ± 11.6 | −2.5 | 53 | 99.0 ± 10.0 | 53 | 92.5 ± 12.9 | −6.6 | 0.03 | 0.03 |
| Hip circumference (cm) | 40 | 117.4 ± 11.9 | 40 | 113.2 ± 13.0 | −3.6 | 53 | 115.8 ± 11.8 | 53 | 107.3 ± 15.0 | −7.4 | 0.02 | 0.03 |
| Body fat (%) | 39 | 47.7 ± 5.4 | 36 | 45.1 ± 7.9 | −5.5 | 53 | 46.3 ± 5.1 | 53 | 41.7 ± 7.0 | −10.1 | 0.04 | 0.16 |
| Trunk fat mass (kg) | 39 | 24.1 ± 6.4 | 36 | 20.9 ± 6.6 | −13.1 | 53 | 23.1 ± 6.0 | 53 | 18.7 ± 6.5 | −19.1 | 0.10 | 0.20 |
| Insulin (μU/mL)5 | 40 | 11.43 (9.8, 13.4) | 40 | 8.95 (7.6, 10.6) | −21.7 | 53 | 10.81 (9.6, 12.2) | 53 | 7.98 (7.0, 9.2) | −26.2 | 0.53 | 0.88 |
| CRP (mg/mL)5 | 40 | 1.75 (1.3, 2.4) | 40 | 1.20 (0.8, 1.7) | −31.5 | 51 | 2.69 (2.0, 3.6) | 52 | 1.56 (1.1, 2.1) | −42.1 | 0.20 | 0.62 |
1
CRP, C-reactive protein; 25(OH)D, 25-hydroxyvitamin D.
2
A general estimating equation model was used to compare the 12-mo change between women who became replete (≥32 ng/mL) and those who did not; all available data, unadjusted.
3
Adjusted for age, race-ethnicity, baseline BMI, baseline serum 25(OH)D, total vitamin D intake (diet + supplements), and total calcium intake (diet + supplements).
4
Mean ± SD (all such values).
5
Log-transformed variables are presented as geometric means (95% CIs).